Skip to main content
Erschienen in: Investigational New Drugs 4/2015

01.08.2015 | PHASE II STUDIES

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

verfasst von: S. M. Reddy, S. Kopetz, J. Morris, N. Parikh, W. Qiao, M. J. Overman, D. Fogelman, I. Shureiqi, C. Jacobs, Z. Malik, C. A. Jimenez, R. A. Wolff, J. L. Abbruzzese, G. Gallick, C. Eng

Erschienen in: Investigational New Drugs | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Summary

Background Src has a critical role in tumor cell migration and invasion. Increased Src activity has been shown to correlate with disease progression and poor prognosis, suggesting Src could serve as a therapeutic target for kinase inhibition. Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor. Methods Metastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study. Saracatinib was administered at 175 mg by mouth daily for 28 day cycles until dose-limiting toxicity or progression as determined by staging every 2 cycles. The primary endpoint was improvement in 4 month progression-free survival. Design of Thall, Simon, and Estey was used to monitor proportion of patients that were progression free at 4 months. The trial was opened with plan to enroll maximum of 35 patients, with futility assessment every 10 patients. Results A total of 10 patients were enrolled between January and November 2007. Further enrollment was stopped due to futility. Median progression-free survival was 7.9 weeks, with all 10 patients showing disease progression following radiographic imaging. Median overall survival was 13.5 months. All patients were deceased by time of analysis. Observed adverse events were notable for a higher than expected number of patients with grade 3 hypophosphatemia (n = 5). Conclusion Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.
Literatur
1.
Zurück zum Zitat Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA: Cancer J Clin 64(2):104–17 Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA: Cancer J Clin 64(2):104–17
2.
Zurück zum Zitat Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol : Off J Am Soc Clin Oncol 22(2):229–37CrossRef Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol : Off J Am Soc Clin Oncol 22(2):229–37CrossRef
3.
Zurück zum Zitat Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE et al (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85(4):786–95PubMedCrossRef Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE et al (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85(4):786–95PubMedCrossRef
4.
Zurück zum Zitat Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61(13):5090–101PubMed Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61(13):5090–101PubMed
5.
Zurück zum Zitat Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol : Off J Am Soc Clin Oncol 27(5):672–80CrossRef Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol : Off J Am Soc Clin Oncol 27(5):672–80CrossRef
6.
Zurück zum Zitat Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563–72PubMedCrossRef Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563–72PubMedCrossRef
7.
Zurück zum Zitat Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N et al (2011) EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res : Off J Am Assoc Cancer Res 17(20):6522–30CrossRef Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N et al (2011) EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res : Off J Am Assoc Cancer Res 17(20):6522–30CrossRef
9.
Zurück zum Zitat Xie G, Peng Z, Raufman JP (2012) Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol 302(9):G1006–15PubMedCentralPubMedCrossRef Xie G, Peng Z, Raufman JP (2012) Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol 302(9):G1006–15PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–8PubMedCrossRef Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–8PubMedCrossRef
11.
Zurück zum Zitat Chen J, Elfiky A, Han M, Chen C, Saif MW (2014) The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer 13(1):5–13PubMedCrossRef Chen J, Elfiky A, Han M, Chen C, Saif MW (2014) The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer 13(1):5–13PubMedCrossRef
12.
Zurück zum Zitat Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS et al (2005) HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24(19):3110–20PubMedCrossRef Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS et al (2005) HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24(19):3110–20PubMedCrossRef
14.
Zurück zum Zitat Cartwright CA, Meisler AI, Eckhart W (1990) Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci U S A 87(2):558–62PubMedCentralPubMedCrossRef Cartwright CA, Meisler AI, Eckhart W (1990) Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci U S A 87(2):558–62PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (2002) Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94(2):344–51PubMedCrossRef Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (2002) Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94(2):344–51PubMedCrossRef
16.
Zurück zum Zitat Talamonti MS, Roh MS, Curley SA, Gallick GE (1993) Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91(1):53–60PubMedCentralPubMedCrossRef Talamonti MS, Roh MS, Curley SA, Gallick GE (1993) Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91(1):53–60PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J et al (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 3(3):248–61PubMedCrossRef Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J et al (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 3(3):248–61PubMedCrossRef
18.
Zurück zum Zitat Investigator’s Brochure AZD0530 (2005) In: AstraZeneca Pharmaceuticals M, Cheshire, England Investigator’s Brochure AZD0530 (2005) In: AstraZeneca Pharmaceuticals M, Cheshire, England
19.
Zurück zum Zitat Hennequin L, Allen J, Costello GF et al (2005) The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Proc Am Assoc Cancer Res 46:A2537 Hennequin L, Allen J, Costello GF et al (2005) The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Proc Am Assoc Cancer Res 46:A2537
20.
Zurück zum Zitat Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI et al (2010) Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res : Off J Am Assoc Cancer Res 16(19):4876–83CrossRef Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI et al (2010) Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res : Off J Am Assoc Cancer Res 16(19):4876–83CrossRef
21.
Zurück zum Zitat Gangadhar TC, Clark JI, Karrison T, Gajewski TF (2013) Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Investig New Drugs 31(3):769–73CrossRef Gangadhar TC, Clark JI, Karrison T, Gajewski TF (2013) Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Investig New Drugs 31(3):769–73CrossRef
22.
Zurück zum Zitat Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K et al (2012) A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investig New Drugs 30(3):1158–63CrossRef Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K et al (2012) A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investig New Drugs 30(3):1158–63CrossRef
23.
Zurück zum Zitat Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D et al (2011) Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 31(1):249–53PubMedCentralPubMed Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D et al (2011) Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 31(1):249–53PubMedCentralPubMed
24.
Zurück zum Zitat Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti-Cancer Drugs 20(3):179–84PubMedCentralPubMedCrossRef Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti-Cancer Drugs 20(3):179–84PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A et al (2011) Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 11(5):306–11PubMedCentralPubMedCrossRef Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A et al (2011) Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 11(5):306–11PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD et al (2014) A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer 85(2):245–50PubMedCrossRef Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD et al (2014) A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer 85(2):245–50PubMedCrossRef
27.
Zurück zum Zitat Messersmith WA NS, Arcaroli J et al. (2010) A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic paancreatic cancer. Journal of Clinical Oncology. Suppl: abstr e14515 Messersmith WA NS, Arcaroli J et al. (2010) A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic paancreatic cancer. Journal of Clinical Oncology. Suppl: abstr e14515
28.
Zurück zum Zitat Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L et al (2014) A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clin Lung Cancer 15(1):52–7PubMedCrossRef Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L et al (2014) A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clin Lung Cancer 15(1):52–7PubMedCrossRef
29.
Zurück zum Zitat Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E et al (2012) A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investig New Drugs 30(2):779–86CrossRef Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E et al (2012) A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investig New Drugs 30(2):779–86CrossRef
30.
Zurück zum Zitat McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M et al (2014) A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 25(10):1988–95CrossRef McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M et al (2014) A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 25(10):1988–95CrossRef
31.
Zurück zum Zitat Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M et al (2004) Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 279(44):46113–21PubMedCrossRef Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M et al (2004) Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 279(44):46113–21PubMedCrossRef
32.
Zurück zum Zitat Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU et al (2009) Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842–9PubMedCentralPubMedCrossRef Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU et al (2009) Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842–9PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA et al (2011) Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30(5):561–74PubMedCentralPubMedCrossRef Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA et al (2011) Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30(5):561–74PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M et al (2008) Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res : Off J Am Assoc Cancer Res 14(13):4284–91CrossRef Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M et al (2008) Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res : Off J Am Assoc Cancer Res 14(13):4284–91CrossRef
35.
Zurück zum Zitat Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD et al (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273(2):1052–7PubMedCrossRef Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD et al (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273(2):1052–7PubMedCrossRef
36.
Zurück zum Zitat Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S et al (2012) Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Investig New Drugs 30(3):1211–5CrossRef Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S et al (2012) Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Investig New Drugs 30(3):1211–5CrossRef
37.
Zurück zum Zitat Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C et al (2014) Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investig New Drugs 32(2):330–9CrossRef Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C et al (2014) Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investig New Drugs 32(2):330–9CrossRef
38.
Zurück zum Zitat Lieu C, Wolff RA, Eng C et al. (2010) Phase 1B study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(15 suppl): Abstract 3536 Lieu C, Wolff RA, Eng C et al. (2010) Phase 1B study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(15 suppl): Abstract 3536
39.
Zurück zum Zitat Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 23(3):610–7CrossRef Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 23(3):610–7CrossRef
40.
Zurück zum Zitat Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T et al (2014) Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist 19(4):348–9PubMedCentralPubMedCrossRef Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T et al (2014) Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist 19(4):348–9PubMedCentralPubMedCrossRef
Metadaten
Titel
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer
verfasst von
S. M. Reddy
S. Kopetz
J. Morris
N. Parikh
W. Qiao
M. J. Overman
D. Fogelman
I. Shureiqi
C. Jacobs
Z. Malik
C. A. Jimenez
R. A. Wolff
J. L. Abbruzzese
G. Gallick
C. Eng
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2015
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-015-0257-z

Weitere Artikel der Ausgabe 4/2015

Investigational New Drugs 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.